Result of AGM

Syncona Limited

01 August 2023

 

Syncona Limited

Result of Annual General Meeting

1 August 2023

At the Annual General Meeting of Syncona Limited (the "Company") held today, all Resolutions as set out in the 'Notice of the 2023 Annual General Meeting' dated 28 June 2023 sent to shareholders of the Company (the "Notice") were duly passed.

Resolutions 1 to 13 were proposed as Ordinary Resolutions. Resolution 14 was proposed as a Special Resolution and Resolution 15 was proposed as an Extraordinary Resolution.

Details of the proxy voting results, which should be read alongside the Notice, are noted below:

No	Resolution	For	Discretion	Against	Abstain (withheld)
1	Receive and consider the Annual Audited Financial Statements of the Company for the year ended 31 March 2023, together with the Reports of the Directors and Auditors therein	509,248,042 (99.99%)	(0) (0%)	9,810 (0.01%)	3,726
2	Re-appointment of Deloitte LLP (Guernsey Branch) as Auditors	499,812,823 (99.99%)	(0) (0%)	64,344 (0.01%)	9,384,411
3	Authorise the Directors to determine the remuneration of the Auditors	499,860,699 (99.99%)	(0) (0%)	16,468 (0.01%)	9,384,411
4	Re-elect Melanie Gee as a Director	506,670,977 (99.49%)	(0) (0%)	2,586,875 (0.51%)	3,726
5	Re-elect Julie Cherrington as a Director	509,234,482 (99.99%)	(0) (0%)	23,370 (0.01%)	3,726
6	Re-elect Cristina Csimma as a Director	509,234,482 (99.99%)	(0) (0%)	23,370 (0.01%)	3,726
7	Re-elect Virginia Holmes as a Director	506,670,977 (99.49%)	(0) (0%)	2,586,875 (0.51%)	3,726
8	Re-elect Robert Hutchinson as a Director	506,636,608 (99.49%)	(0) (0%)	2,616,589 (0.51%)	8,381
9	Re-elect Kemal Malik as a Director	506,636,608 (99.49%)	(0) (0%)	2,616,589 (0.51%)	8,381
10	Re-elect Gian Piero Reverberi as a Director	506,636,608 (99.49%)	(0) (0%)	2,616,589 (0.51%)	8,381

11	Approve the report on implementation of the Remuneration Policy for Non-Executive Directors	509,148,250 (99.94%)	211,077 (0.04%)	93,843 (0.02%)	14,961
12	Approve the Company's Remuneration Policy	509,149,180 (99.98%)	(0) (0%)	101,934 (0.02%)	10,464
13	Authority to allot and issue shares, as set out in the Notice	508,406,358 (99.83%)	(0) (0%)	848,009 (0.17%)	7,211
14	Authorise the Company to purchase its own shares, as set out in the Notice	507,133,706 (99.58%)	(0) (0%)	2,124,146 (0.42%)	3,726
15	Disapply pre-emption rights, as set out in the Notice	487,907,670 (98.37%)	(0) (0%)	8,081,414 (1.63%)	13,272,494

A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.

In accordance with the Listing Rule 9.6.2, a copy of all the resolutions passed other than resolutions concerning ordinary business have been submitted to the Financial Conduct Authority via the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

The full text of the resolutions can be found in the Notice, which is available on the Company's website at https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/.

Enquiries

Syncona Limited
Annabel Clark / Fergus Witt

Tel: [phone]

FTI Consulting

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: [phone]

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by creating and building companies to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic areas, for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

 

END